Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$1.42
EPS est.
$1.14
EPS surprise
+24.78%
1-day move
-9.70%
Insulet Corporation reported better-than-expected earnings per share, but the stock fell by 9.7% in response. The decline may be attributed to the lack of revenue information and guidance, leaving investors uncertain about future performance. Overall, the strong EPS surprise contrasts with the missing revenue details, which could have contributed to the negative stock reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.42 | $1.19 | +24.78% |
| Revenue | N/A | $730M | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Insulet Corporation (PODD) is a healthcare company that specializes in developing and manufacturing innovative insulin delivery systems for people with diabetes. With a market cap of $12 billion, Insulet plays a crucial role in the health care equipment sector, focusing on improving the quality of life for diabetes patients through its Omnipod product line.
Last quarter
In Q4 2025, Insulet reported an EPS of $1.55, exceeding estimates by 4.87%, which led to a positive stock reaction of 4.76% the following day. However, revenue details were not disclosed, leaving some uncertainty about overall sales performance.
Management promises and guidance
EPS beat streak
5Q
EPS beat rate
88%
Avg EPS surprise
+11.63%
Avg 1-day reaction
-1.44%
Analysts are cautiously optimistic about Insulet's upcoming earnings, with expectations for solid EPS and revenue growth. However, there are concerns about potential market saturation and competition in the diabetes management sector.
Bull case
If Insulet beats expectations, it could signal strong demand for its products and effective cost management, potentially driving the stock higher.
Bear case
Conversely, if the company misses estimates, it may indicate challenges in sales or increased competition, leading to a negative market reaction.
Key metrics to watch
EPS
$1.19Earnings per share is a key indicator of the company's profitability and will show how well Insulet is managing its costs and revenue.
Revenue
$730MTotal revenue reflects the company's sales performance and growth trajectory, crucial for understanding market demand for its products.
The print will turn on these.
Q1
Will the EPS meet or exceed the consensus estimate of $1.19?
A strong EPS could indicate effective cost management and robust demand for Insulet's products, which is crucial for investor confidence.
Q2
What are the revenue figures compared to the consensus of $730M?
Revenue performance will provide insight into the company's market position and growth potential, impacting future projections.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating Insulet's growth potential given its recent product innovations and market expansion efforts. There is a strong chance that demand for its Omnipod systems is increasing faster than anticipated.
Supporting evidence
Insulet has consistently beaten EPS estimates in recent quarters, suggesting strong operational performance.
The options market is pricing in a larger move than historical averages, indicating heightened expectations.
Recent product launches have received positive feedback, which may not be fully reflected in analyst estimates.
Key risk
If revenue growth significantly exceeds $730M, it could challenge the current market outlook.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it reflects Insulet's ability to navigate a competitive landscape while maintaining growth.
Bull confirmed if
An EPS of $1.25 or higher with revenue exceeding $735M would confirm strong operational performance.
Bear confirmed if
An EPS below $1.06 or revenue falling short of $713M would raise concerns about market demand and competition.
What the market is pricing for the move.
Implied Move
±11.73%
Historical Avg
±6.7%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±12.0% while PODD has averaged ±6.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
51.3%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
106.95%
of float
Insider
0.33%
of float
Holders
1,088
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
6,690,192 sh · $898.9M
9.65%
4.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Insulet beats expectations, history suggests the stock could rise by an average of 3.7%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline, with historical data indicating an average drop of 1.1% following such outcomes.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
1 buy·1 sell
Members
2
House + Senate
Est. Notional
$101,002.00–$265,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
4,525,333 sh · $608.0M
6.52%
-1.2%
State Street Corporation
3,197,555 sh · $429.6M
4.61%
5.1%
Vanguard Portfolio Management LLC
3,075,932 sh · $413.3M
4.44%
-10.8%
AQR Capital Management, LLC
2,455,135 sh · $329.9M
3.54%
53.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
1 trade
Net selling
Recent Transactions
Traded Aug 18, 2026 · disclosed Sep 10, 2026
$1,001.00–$15,000.00
Traded May 7, 2026 · disclosed May 10, 2026
$100,001.00–$250,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.